How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
Jan. 5 2018, Updated 10:35 a.m. ET
Hemophilia segment revenue trends
In 3Q17, Novo Nordisk’s (NVO) Hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis. In 3Q17, Novo Nordisk’s NovoSeven generated revenues of 2.1 billion DKK, which reflected ~8% growth on a YoY basis. In 3Q17, in the US, Europe, AAMEO, China, Japan & Korea, and Latin America, NovoSeven generated revenues of 1.0 billion DKK, 484 million DKK, 224 million DKK, 52 million DKK, 123 million DKK, and 135 million DKK, respectively.
In 3Q17, NovoEight generated revenues of 253 million DKK, which reflected ~23% growth on a YoY basis. In 3Q17, in the US, Europe, AAMEO, Japan & Korea, and Latin America, NovoEight generated revenues of 46 million DKK, 139 million DKK, 21 million DKK, 42 million DKK, and 5 million DKK, respectively.
9M17 revenue trends
Novo Nordisk’s Hemophilia segment reported revenues for the first nine months of 2017 (or 9M17) of 7.7 billion DKK, which reflected ~15% growth on a YoY basis.
NovoSeven reported 9M17 revenues of 6.8 billion DKK, which reflected a ~2% decline on a YoY basis. In the US, Europe, AAMEO, China, Japan & Korea, and Latin America, NovoSeven generated revenues of 3.3 billion DKK, 1.7 billion DKK, 753 million DKK, 163 million DKK, 359 million DKK, 359 million DKK, and 378 million DKK, respectively.
NovoEight reported 9M17 revenues of 829 million DKK, which reflected ~35% growth on a YoY basis. In the US, Europe, AAMEO, China, Japan & Korea, and Latin America, NovoEight reported 9M17 revenues of 246 million DKK, 413 million DKK, 35 million DKK, 1 million DKK, 125 million DKK, and 9 million DKK, respectively.
Human growth disorder drug revenue trends
In 3Q17, Novo Nordisk’s human growth disorders products reported revenues of 4.9 billion DKK, which reflected a ~24% decline on a YoY basis.
In 3Q17, in the US, Europe, AAMEO, China, Japan & Korea, and Latin America, human growth hormone products generated revenues of 1.8 billion DKK, 1.2 billion DKK, 541 million DKK, 11 million DKK, 1.2 billion DKK, and 198 million DKK, respectively.
In 3Q17, Novo Nordisk’s peers in the hemophilia drug market Shire (SHPG), Bayer (BAYZF), and Pfizer (PFE) reported revenues of $3.7 billion, 8.0 billion euros, and $13.2 billion, respectively. The Pharmaceutical ETF (PPH) invests ~4.9% of its total portfolio holding in Novo Nordisk.
